All News
Worse Outcomes in HLA-B27+ JIA
d
MedPage Today
Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term outcomes, including lower rates of drug-free remission, in a prospective Scandinavian study.
Read Article
Predicting Premature Death with Multimorbidity
Machine learning (ML) models were used to predict premature death in inflammatory bowel disease (IBD) patients with multimorbidity, the co-occurrence of 2 or more chronic conditions.
Treating chronic inflammatory diseases with JAK inhibitors
d
Science Daily
Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.
Peripheral Nerve Blocks for Hip Fractures
JAMA reviews the use of peripheral nerve block with hip fractures as an effective pain management strategy that can be performed by credentialed clinicians outside of the operating room.
Read Article
A study in mice shows that JAK inhibition In mice model of status epilepticus (SE) didnt prevent initial SE but when did effect chronic phase of Sz weeks after SE induction of SE, suppressing seizures, and epilepsy-associated histopathological alterations. Sz suppression lasted https://t.co/GMIPCtoc7x
Dr. John Cush RheumNow ( View Tweet)
ACPA specificity and recognition motifs examined in 6,907 patients with RA from 5 Scandinavian cohorts. ACPA targeting non-glycine citrulline motifs assoc. more strongly w/ HLA-SE; ACPA to glycine citrulline motifs assoc. w/ smoking and IgA ACPA
A&R
https://t.co/PmKv3dZLc4 https://t.co/NdPG4Orfj4
Links:
ACR_Journals ACR_Journals ( View Tweet)
Autoimmune Disease Impact Report
Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: https://t.co/TfXZti5NN3
Dr. John Cush RheumNow ( View Tweet)
2024 Rheumatology Year in Review
2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians.
https://t.co/JjG8oYTkKQ https://t.co/YgHMMiAQ9Z
Links:
Dr. John Cush RheumNow ( View Tweet)
The British Society for Rheumatology (BSR) guidelines 2024 for the management of Sjogren’s Syndrome. Summary slide of key recommendations. https://t.co/qBuCFM8MnX https://t.co/DYgGzAgISa
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Dr. Swamy Venuturupalli, a Community Practice Innovation Award recipient, is transforming telehealth in rheumatology! His project introduces an innovative app that empowers patients to examine their own joints—making high-quality telehealth a seamless part of care. https://t.co/R5M4jtVz5m
Rheumatology Research Foundation RheumResearch ( View Tweet)
#Thrombocytopenia is common in #antiphospholipid syndrome (APS), and is likely associated with more severe disease. Although the pathophysiology underlying thrombocytopenia in APS has yet to be definitively revealed, mechanisms that play a role (at least in subsets of patients) https://t.co/pUXmb1irbw
Alberto Giraldo alb_giraldo ( View Tweet)
THERE’S STILL TIME to join us for #SOTA25, April 4-6 in Chicago! Secure your seat TODAY for a weekend of #rheum education, connection, & innovation → https://t.co/DEmGVZO5Af https://t.co/1D2j2enA2X
Links:
American College of Rheumatology ACRheum ( View Tweet)
Of >105,000 participants with 30-year follow-up, only 9.3% achieved healthy aging (age 70, w/o any chronic diseases). Their diet was significantly associated with this outcome🧵 @NatureMedicine https://t.co/VHxmdLvoDe
Eric Topol EricTopol ( View Tweet)
• Don't be afraid of being different.
• Take risks.
• Be curious.
• Don't be afraid to fail.
• Work hard for the things you love the most. https://t.co/7OeB5WfnNy
Prof. Feynman ProfFeynman ( View Tweet)
Congratulation to all the MSIVs who matched last week - Looking forward to ya'll becoming RHEUMATOLOGISTs of the futre https://t.co/NAePO72j9Z
Dr. John Cush RheumNow ( View Tweet)
Disease activity during Pregnancy in Rheumatoid arthritis and Spondyloarthritis
A prospective French study of rheumatoid arthritis (RA) or spondyloarthritis (SpA) patients showed that most maintained stable disease activity during pregnancy, but over one-third flared and https://t.co/3k6ZJTybAb
Dr. John Cush RheumNow ( View Tweet)
Increasing Prevalence of Osteoporosis
Research published in Osteoporosis International studied NHANES data showed increasing trends in osteoporosis in the United States of America.
https://t.co/9Ic2e6kaFR https://t.co/tVmFAp7EVe
Dr. John Cush RheumNow ( View Tweet)
Full read Overview of the effects of Menopause and Estrogen on autoimmune disorders https://t.co/NpVPrnPT6x https://t.co/wt9f5D7WXL
Dr. John Cush RheumNow ( View Tweet)
Post hoc analysis of 5 ph III Belimumab RCTs (BLISS, etc, N=3086) on skin outcomes BILAG & SLEDAI-2K), BEL was superior to PBO (mcBILAG OR: 1.29; mcSLEDAI-2K OR: 1.37). Also if SLEDAI ≥10 & dsDNA+ pts. BEL prevented skin flares (HR 0.70) https://t.co/p1MVVf97Go https://t.co/qwWUyegpyi
Dr. John Cush RheumNow ( View Tweet)
55 myositis (IIM) pts studied Nailfold Capillaries, MSAbs, cytokines & IFN genes. MDA5(+) pts signif more dilated (DIL), giant & abnl morphology caps, w/ microhemorrhages (MH) vs ARS (+) pts. MH & DIL assoc w/ MX1, IFI27, IP-10, RANTES, GROα. Giant caps assoc w/ IFI27, SDF-1α, https://t.co/3WQL8Sw0rq
Dr. John Cush RheumNow ( View Tweet)